Development of a method to quantify total and free irinotecan and 7-ethyl-10-hydroxycamptothecin (SN-38) for pharmacokinetic and bio-distribution studies after administration of irinotecan liposomal formulation
In 2015, liposomal formulation of irinotecan (ONIVYDE) has been approved by FDA and widely applied in the treatment of pancreatic cancer. ONIVYDE is a novel liposome formulation, entrapping CPT-11 in the aqueous core of vesicles using a modified gradient loading method. Due to toxicity concerns, it...
Main Authors: | Wenqian Yang, Zimeng Yang, Jieru Liu, Dan Liu, Yongjun Wang |
---|---|
Format: | Article |
Language: | English |
Published: |
Elsevier
2019-11-01
|
Series: | Asian Journal of Pharmaceutical Sciences |
Online Access: | http://www.sciencedirect.com/science/article/pii/S1818087618302630 |
Similar Items
-
P-glycoprotein-dependent pharmacokinetics of irinotecan and its active metabolite, SN-38 in rats: Effect of verapamil
by: Tripta Garg, et al.
Published: (2015-03-01) -
Development of pilot technology for liposomal irinotecan production
by: O. V. Stadnichenko, et al.
Published: (2018-08-01) -
Human Serum Albumin Conjugates of 7-Ethyl-10-hydroxycamptothecin (SN38) for Cancer Treatment
by: Nima Sepehri, et al.
Published: (2014-01-01) -
Synthesis and Biological Evaluation of Novel 10-Substituted-7-ethyl-10-hydroxycamptothecin (SN-38) Prodrugs
by: Mo Zhou, et al.
Published: (2014-11-01) -
Factors affecting the pharmacokinetics and pharmacodynamics of PEGylated liposomal irinotecan (IHL-305) in patients with advanced solid tumors
by: Wu H, et al.
Published: (2015-02-01)